Targeting Protein Kinase G to Treat Cardiac Proteotoxicity

Christian U. Oeing, Sumita Mishra, Brittany L. Dunkerly-Eyring, Mark J. Ranek

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Impaired or insufficient protein kinase G (PKG) signaling and protein quality control (PQC) are hallmarks of most forms of cardiac disease, including heart failure. Their dysregulation has been shown to contribute to and exacerbate cardiac hypertrophy and remodeling, reduced cell survival and disease pathogenesis. Enhancement of PKG signaling and PQC are associated with improved cardiac function and survival in many pre-clinical models of heart disease. While many clinically used pharmacological approaches exist to stimulate PKG, there are no FDA-approved therapies to safely enhance cardiomyocyte PQC. The latter is predominantly due to our lack of knowledge and identification of proteins regulating cardiomyocyte PQC. Recently, multiple studies have demonstrated that PKG regulates PQC in the heart, both during physiological and pathological states. These studies tested already FDA-approved pharmacological therapies to activate PKG, which enhanced cardiomyocyte PQC and alleviated cardiac disease. This review examines the roles of PKG and PQC during disease pathogenesis and summarizes the experimental and clinical data supporting the utility of stimulating PKG to target cardiac proteotoxicity.

Original languageEnglish (US)
Article number858
JournalFrontiers in Physiology
StatePublished - Jul 28 2020


  • PKG
  • autophagy
  • heart failure
  • proteasome
  • proteostasis
  • proteotoxicity

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)


Dive into the research topics of 'Targeting Protein Kinase G to Treat Cardiac Proteotoxicity'. Together they form a unique fingerprint.

Cite this